Skip to main content

Table 3 Clinical outcomes of patients in different groups

From: Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer

Indicator

Obs group (n = 50)

Ctrl group (n = 50)

P

Gender

Males

27

29

> 0.05

Females

23

21

Age (years old)

56.13 ± 4.72

54.58 ± 5.37

> 0.05

Disease duration (years)

1.89 ± 0.45

2.04 ± 0.39

> 0.05

BCLC staging

B

20

18

> 0.05

C

30

32

Tumor dimeter (cm)

>= 5

38

39

> 0.05

< 5

12

11

Cancer embolus

Yes

29

28

> 0.05

No

21

22

Extrahepatic metastasis

Yes

33

31

> 0.05

No

7

9